骨髓纤维化患者基因表达谱与分子及临床特征相关
该研究对114例骨髓纤维化(MF)患者的外周血粒细胞进行微阵列基因表达谱(GEP)分析,通过Cox回归识别出201个与生存相关的转录本,并据此定义高风险基因特征。高风险组总生存和无白血病生存均较差,且富集高危分子突变、 post-PV/ET MF及JAK2V617F纯合子,低风险组则多见pre-PMF。结果表明GEP与MF患者分子及临床特征相关,尤其与生存相关,提示GEP可能提供补充性预后信息。
要点
- 基于201个生存相关转录本的基因特征可区分MF患者的高死亡风险。
- 高风险组总生存和无白血病生存较差,且富集高危分子突变。
- 高风险组富集post-PV/ET MF和JAK2V617F纯合子,低风险组多见pre-PMF。
核心结论
- MF患者粒细胞基因表达谱与分子和临床特征相关,尤其与生存相关。
- GEP可能为临床决策提供补充性预后信息,但仅为概念验证。
研究设计与样本
- 研究纳入114例骨髓纤维化患者,采用微阵列平台检测外周血粒细胞基因表达谱。
- 通过Cox回归分析识别与生存相关的转录本。
主要发现
- Cox回归识别出201个生存相关转录本,可区分高死亡风险患者。
- 高风险组总生存和无白血病生存均较差,并富集当代预后模型中的临床和分子不良特征,包括高危分子突变。
- 高风险组富集post-PV和post-ET MF及JAK2V617F纯合子患者;低风险组中pre-PMF更常见。
关键数值与推荐
- 201个生存相关转录本构成高风险基因特征。
- 高风险组总生存和无白血病生存较差。
临床怎么用
- GEP可能作为现有预后模型的补充工具,辅助MF患者的临床决策。
- 目前仅为概念验证,尚不能直接用于常规临床实践。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Myelofibrosis (MF) belongs to the family of classic Philadelphia-negative myeloproliferative neoplasms (MPNs). It can be primary myelofibrosis (PMF) or secondary myelofibrosis (SMF) evolving from polycythemia vera (PV) or essential thrombocythemia (ET). Despite the differences, PMF and SMF patients are currently managed in the same way, and prediction of survival is based on the same clinical and genetic features. In the last few years, interest has grown concerning the ability of gene expression profiles (GEPs) to provide valuable prognostic information. Here, we studied the GEPs of granulocytes from 114 patients with MF, using a microarray platform to identify correlations with patient characteristics and outcomes. Cox regression analysis led to the identification of 201 survival-related transcripts characterizing patients who are at high risk for death. High-risk patients identified by this gene signature displayed an inferior overall survival and leukemia-free survival, together with clinical and molecular detrimental features included in contemporary prognostic models, such as the presence of high molecular risk mutations. The high-risk group was enriched in post-PV and post-ET MF and JAK2V617F homozygous patients, whereas pre-PMF was more frequent in the low-risk group. These results demonstrate that GEPs in MF patients correlate with their molecular and clinical features, particularly their survival, and represent the proof of concept that GEPs might provide complementary prognostic information to be applied in clinical decision making.
引用
- Rontauroli S, Castellano S, Guglielmelli P, et al. Gene expression profile correlates with molecular and clinical features in patients with myelofibrosis. Blood Adv. 2021. PMID: 33666652. doi:10.1182/bloodadvances.2020003614
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。